Speech-Language Pathologists in Breese, IL Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Mrs. Monica J Koch, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 777 Memorial Dr, Breese, IL 62230 Phone: 618-526-7128

Mrs. Maribeth Detmer, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1665 N 4th St, Breese, IL 62230 Phone: 618-526-8830

Elyse Haake Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1036 Vossclare Ln, Breese, IL 62230 Phone: 618-971-7465

Olivia Hodges Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 950 N 4th St, Breese, IL 62230 Phone: 618-795-3431

Susan Mary Bickline, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9515 Holy Cross Ln, Box 99, Breese, IL 62230 Phone: 618-526-4511    Fax: 618-526-2855

Jennifer Jo Klostermann, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 777 Memorial Dr, Breese, IL 62230 Phone: 618-526-7128

News Archive

Novel interventional radiology procedure zaps around complicated pancreatic tumors

Results of a study presented at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif., signal a light at the end of the tunnel for individuals with inoperable locally advanced pancreatic cancer (LAPC). A new procedure called irreversible electroporation or IRE uses microsecond electrical pulses to force open and destroy tumor cells around a vast and delicate network of blood vessels of the pancreas.

Adding protein sarcospan to muscle cells might help Duchenne muscular dystrophy

The overlooked and undervalued protein, sarcospan, just got its moment in the spotlight.

Study highlights pernicious effect of obesity on blood-making stem cells

New research published in the Journal of Experimental Medicine highlights the pernicious effect of obesity on the long-term health of blood-making stem cells (hematopoietic stem cells).

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

Idera Pharmaceuticals, Inc. today presented data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments, rituximab or bortezomib, significantly increased antitumor activity in several preclinical lymphoma models. The presentation, entitled "Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies," was made at the 52nd Annual Meeting of the American Society for Hematology in Orlando, Florida by Idera scientists.

Read more Medical News

› Verified 3 days ago